A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR⁺CXCL-CXCR1/2 Pathway Inhibitor

Area of Science:

• Oncology
• Pharmacology

Background:

• CXCR1/2 biomolecules are implicated in cancer progression, inflammation, and angiogenesis.
• Overexpression of CXCR1/2 is noted in clear cell renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC).
• Targeting the ELR+CXCL-CXCR1/2 pathway presents a therapeutic opportunity.

Purpose of the Study:

• To investigate novel N,N'-diarylurea analogues as inhibitors of the ELR+CXCL-CXCR1/2 pathway.
• To evaluate the efficacy of these compounds in RCC and HNSCC models.
• To identify lead compounds for potential anticancer drug development.

Main Methods:

• Synthesis and evaluation of N,N'-diarylurea analogues.
• In vitro assays using RCC and HNSCC cell lines and 3D spheroid cultures.
• In vivo studies in zebrafish embryos and RCC xenografted mice.

Main Results:

• Compound 10 demonstrated significant inhibition of cancer cell invasion, migration, and neo-angiogenesis.
• Compound 10 interfered with key signaling pathways with high kinase selectivity.
• In vivo studies showed notable anticancer, antimetastatic, and antiangiogenic effects with minimal toxicity upon oral administration.

Conclusions:

• Compound 10 is a potent inhibitor of the ELR+CXCL-CXCR1/2 pathway.
• Compound 10 exhibits significant anticancer, antimetastatic, and antiangiogenic properties in preclinical models.
• Compound 10 is a promising candidate for further development as an oral anticancer and antiangiogenic therapeutic.